Since the first prospective TFR trial (the STIM-1 study in 2007), more than 2000 CML patients worldwide have pursued TKI discontinuation in a clinical trial [55]. This evidence concerns the gene STIM1 and chronic myelogenous leukemia, BCR-ABL1 positive.